In today’s session Diplomat Pharmacy Inc (DPLO) registered an unusually high (1,062) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious DPLO increase. With 1,062 contracts traded and 1834 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: DPLO161118C00025000 closed last at: $0.95 or 38.7% down. About 325,441 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 15.53% since March 30, 2016 and is downtrending. It has underperformed by 18.54% the S&P500.
Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage
Out of 8 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Diplomat Pharmacy has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, October 21 by UBS. The rating was upgraded by Bank of America to “Neutral” on Wednesday, October 14. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Market Perform” rating by Cowen & Co on Friday, June 24. Morgan Stanley downgraded it to “Equal-Weight” rating and $31 target price in Friday, October 2 report. The rating was maintained by Mizuho with “Buy” on Wednesday, October 21. As per Wednesday, May 11, the company rating was maintained by Mizuho. As per Tuesday, August 4, the company rating was maintained by Leerink Swann. The rating was initiated by Barclays Capital on Wednesday, January 6 with “Overweight”. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Neutral” rating by Bank of America on Tuesday, June 7.
According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”
Insitutional Activity: The institutional sentiment decreased to 1.43 in 2016 Q2. Its down 0.22, from 1.65 in 2016Q1. The ratio worsened, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Legal General Gp Inc Public Ltd Limited Liability Company has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Weatherbie Cap Limited Liability accumulated 1.29% or 259,175 shares. National Bank & Trust Of New York Mellon accumulated 0.01% or 489,176 shares. Moreover, Mirae Asset Glob Ltd has 0.03% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 28,697 shares. Finemark Savings Bank Trust has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Capstone Asset Mngmt Co holds 0.01% or 10,910 shares in its portfolio. Voya Inv accumulated 19,601 shares or 0% of the stock. First Retail Bank Of Omaha holds 0.04% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 16,025 shares. Envestnet Asset Mngmt, a Illinois-based fund reported 17,494 shares. Hood River Cap Mgmt Llc, a Oregon-based fund reported 265,388 shares. The Alabama-based Wealthtrust has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Zurcher Kantonalbank (Zurich Cantonalbank) has 967 shares for 0% of their US portfolio. Teton Inc reported 49,255 shares or 0.16% of all its holdings. Redwood Investments Limited Company, a Massachusetts-based fund reported 127,107 shares. Clearbridge Investments Lc last reported 0.05% of its portfolio in the stock.
Insider Transactions: Since May 2, 2016, the stock had 0 buys, and 2 selling transactions for $1.04 million net activity. Shares for $371,879 were sold by Kaddis Atheer A on Monday, May 2.
Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company has a market cap of $1.53 billion. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. It has a 34.87 P/E ratio. The Firm operates through specialty pharmacy services segment.
DPLO Company Profile
Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
More news for Diplomat Pharmacy Inc (NYSE:DPLO) were recently published by: Fool.com, which released: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. Blogs.Wsj.com‘s article titled: “CFO Moves: Newmont Mining, Varian Medical Systems, Diplomat Pharmacy, Nokia” and published on October 27, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.